Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Chairperson
Gregory H Reaman
FDA-CDER, Silver Spring, MD, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Invited Speaker
Nancy F Goodman
Kids v. Cancer, Washington, DC, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Invited Speaker
D William Parsons
Baylor College of Medicine, Dan L. Duncan Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Invited Speaker
Gilles Vassal
Inst. Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Invited Speaker
Brenda J Weigel
Univ. of Minnesota, Minneapolis, MN, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Invited Speaker
Lisa Bollinger
Amgen, Thousand Oaks, CA, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
FDARA 2017: Impact on Pediatric Cancer Drug Development
Gregory H Reaman
FDA-CDER, Silver Spring, MD, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
Implications of the 2017 FDA Reauthorization Act (FDARA) on Pediatric Cancer Drug Development
Panel Discussion
Gregory H Reaman
FDA-CDER, Silver Spring, MD, United States
Nancy F Goodman
Kids v. Cancer, Washington, DC, United States
D William Parsons
Baylor College of Medicine, Dan L. Duncan Cancer Ctr., Houston, TX, United States
Gilles Vassal
Inst. Gustave Roussy, Villejuif, France
Brenda J Weigel
Univ. of Minnesota, Minneapolis, MN, United States
Lisa Bollinger
Amgen, Thousand Oaks, CA, United States
from AACR Annual Meeting 2018 on April 17, 2018 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8